Skip to main content
Top

10-11-2016 | Skin cancers | Article

Obesity as a risk factor for malignant melanoma and non-melanoma skin cancer

Journal: Reviews in Endocrine and Metabolic Disorders

Authors: K. Karimi, T. H. Lindgren, C. A. Koch, Robert T. Brodell

Publisher: Springer US

Abstract

The dramatic increases in incidence of both obesity and many cancers including skin cancer emphasize the need to better understand the pathophysiology of both conditions and their connections. Melanoma is considered the fastest growing cancer and rates of non-melanoma skin cancer have also increased over the last decade. The molecular mechanisms underlying the association between obesity and skin cancer are not clearly understood but emerging evidence points to changes in the tumor microenvironment including aberrant cell signaling and genomic instability in the chronic inflammatory state many obese individuals experience. This article reviews the literature linking obesity to melanoma and non-melanoma skin cancer.
Literature
1.
Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–65. doi:10.​1634/​theoncologist.​2009-0285.PubMedPubMedCentralCrossRef
2.
Gallagher E, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727–48.PubMedPubMedCentralCrossRef
3.
Albanes D, Winick M. Are cell number and cell proliferation risk factors for cancer? J Natl Cancer Inst. 1988;80(10):772–4.PubMedCrossRef
4.
Scrimshaw NS, SanGiovanni JP. Synergism of nutrition, infection, and immunity: an overview. Am J Clin Nutr. 1997;66(2):464S–77S.PubMed
5.
Koch CA, Diamanti-Kandarakis E. Introduction to endocrine disrupting chemicals—is it time to act? Rev Endocr Metab Disord. 2015;16(4):269–70.PubMedCrossRef
6.
Kirkpatrick CS, White E, Lee JA. Case–control study of malignant melanoma in Washington State. II. Diet, alcohol, and obesity. Am J Epidemiol. 1994;139(9):869–80.PubMed
7.
Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni Jr JF. Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006;17(7):901–9. doi:10.​1007/​s10552-006-0023-9.PubMedCrossRef
8.
Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni Jr JF. Obesity and cancer risk among White and Black United States veterans. Cancer Causes Control. 2004;15(1):35–43. doi:10.​1023/​B:​CACO.​0000016573.​79453.​ba.PubMedCrossRef
9.
Dubin N, Moseson M, Pasternack BS. Epidemiology of malignant melanoma: pigmentary traits, ultraviolet radiation, and the identification of high-risk populations. Recent Results Cancer Res. 1986;102:56–75.PubMedCrossRef
10.
Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C. Oncology Study Group of the Italian Group for Epidemiologic Research in D. Anthropometric measures and risk of cutaneous malignant melanoma: a case–control study from Italy. Melanoma Res. 2006;16(1):83–7. doi:10.​1097/​01.​cmr.​0000194429.​77643.​76.PubMedCrossRef
11.
Dennis LK, Lowe JB, Lynch CF, Alavanja MC. Cutaneous melanoma and obesity in the Agricultural Health Study. Ann Epidemiol. 2008;18(3):214–21. doi:10.​1016/​j.​annepidem.​2007.​09.​003.PubMedPubMedCentralCrossRef
12.
Tang JY, Henderson MT, Hernandez-Boussard T, Kubo J, Desai M, Sims ST, et al. Lower skin cancer risk in women with higher body mass index: the women’s health initiative observational study. Cancer Epidemiol Biomarkers Prev. 2013;22(12):2412–5. doi:10.​1158/​1055-9965.​EPI-13-0647.PubMedCrossRef
13.
Pothiawala S, Qureshi AA, Li Y, Han J. Obesity and the incidence of skin cancer in US Caucasians. Cancer Causes Control : CCC. 2012;23(5):717–26. doi:10.​1007/​s10552-012-9941-x.PubMedPubMedCentralCrossRef
14.
Sergentanis TN, Antoniadis AG, Gogas HJ, Antonopoulos CN, Adami HO, Ekbom A, et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case–control studies. Eur J Cancer. 2013;49(3):642–57. doi:10.​1016/​j.​ejca.​2012.​08.​028.PubMedCrossRef
15.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.​1016/​S0140-6736(08)60269-X.PubMedCrossRef
16.
Dobbins M, Decorby K, Choi BC. The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med. 2013;2013:680536. doi:10.​5402/​2013/​680536.PubMedPubMedCentralCrossRef
17.
Veierod MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer. 1997;71(4):600–4.PubMedCrossRef
18.
Olsen CM, Green AC, Zens MS, Stukel TA, Bataille V, Berwick M, et al. Anthropometric factors and risk of melanoma in women: a pooled analysis. Int J Cancer. 2008;122(5):1100–8. doi:10.​1002/​ijc.​23214.PubMedCrossRef
19.
Praestegaard C, Kjaer SK, Christensen J, Tjonneland A, Halkjaer J, Jensen A. Obesity and risks for malignant melanoma and non-melanoma skin cancer: results from a large Danish prospective cohort study. J Invest Dermatol. 2015;135(3):901–4. doi:10.​1038/​jid.​2014.​438.PubMedCrossRef
20.
Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006;393(Pt 1):7–20. doi:10.​1042/​BJ20051578.PubMedCrossRef
21.
Courneya KS, Katzmarzyk PT, Bacon E. Physical activity and obesity in Canadian cancer survivors: population-based estimates from the 2005 Canadian Community Health Survey. Cancer. 2008;112(11):2475–82. doi:10.​1002/​cncr.​23455.PubMedCrossRef
22.
Sahl WJ, Glore S, Garrison P, Oakleaf K, Johnson SD. Basal cell carcinoma and lifestyle characteristics. Int J Dermatol. 1995;34(6):398–402.PubMedCrossRef
23.
Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–7.PubMedCrossRef
24.
Brandon EL, Gu JW, Cantwell L, He Z, Wallace G, Hall JE. Obesity promotes melanoma tumor growth: role of leptin. Cancer Biol Ther. 2009;8(19):1871–9.PubMedPubMedCentralCrossRef
25.
Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status and obesity in adult populations of developing countries: a review. Bull World Health Organ. 2004;82(12):940–6.PubMed
26.
Popkin BM, Gordon-Larsen P. The nutrition transition: worldwide obesity dynamics and their determinants. Int J Obes Relat Metab Disord. 2004;28 Suppl 3:S2–9. doi:10.​1038/​sj.​ijo.​0802804.PubMedCrossRef
27.
Li X, Liang L, Zhang M, Song F, Nan H, Wang LE, et al. Obesity-related genetic variants, human pigmentation, and risk of melanoma. Hum Genet. 2013;132(7):793–801. doi:10.​1007/​s00439-013-1293-4.PubMedPubMedCentralCrossRef
28.
Frisancho AR, Wainwright R, Way A. Heritability and components of phenotypic expression in skin reflectance of Mestizos from the Peruvian lowlands. Am J Phys Anthropol. 1981;55(2):203–8. doi:10.​1002/​ajpa.​1330550207.PubMedCrossRef
29.
Harrison GA, Owen JJ. Studies on the inheritance of human skin colour. Ann Hum Genet. 1964;28:27–37.PubMedCrossRef
30.
Turner JB, Kumar A, Koch CA. The effects of indoor and outdoor temperature on metabolic rate and adipose tissue—the Mississippi perspective on the obesity epidemic. Rev Endocr Metab Disord. 2016;17(1):61–71. doi:10.​1007/​s11154-016-9358-z.PubMedCrossRef
31.
Tai N, Wong FS, Wen L. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity. Rev Endocr Metab Disord. 2015;16(1):55–65. doi:10.​1007/​s11154-015-9309-0.PubMedPubMedCentralCrossRef
32.
Gerstenblith MR, Shi J, Landi MT. Genome-wide association studies of pigmentation and skin cancer: a review and meta-analysis. Pigment Cell Melanoma Res. 2010;23(5):587–606. doi:10.​1111/​j.​1755-148X.​2010.​00730.​x.PubMedPubMedCentralCrossRef
33.
Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer. 2009;125(4):909–17. doi:10.​1002/​ijc.​24327.PubMedPubMedCentralCrossRef
34.
McAllister EJ, Dhurandhar NV, Keith SW, Aronne LJ, Barger J, Baskin M, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr. 2009;49(10):868–913. doi:10.​1080/​1040839090337259​9.PubMedPubMedCentralCrossRef
35.
Charriere G, Cousin B, Arnaud E, Andre M, Bacou F, Penicaud L, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem. 2003;278(11):9850–5. doi:10.​1074/​jbc.​M210811200.PubMedCrossRef
36.
Wang J, Ding N, Li Y, Cheng H, Wang D, Yang Q, et al. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget. 2015;6(24):20636–49.PubMedPubMedCentralCrossRef
37.
Wang H, Ye J. Regulation of energy balance by inflammation: common theme in physiology and pathology. Rev Endocr Metab Disord. 2015;16(1):47–54.PubMedPubMedCentralCrossRef
38.
Kloting N, Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15(4):277–87.PubMedCrossRef
39.
Ngo HT, Hetland RB, Nygaard UC, Steffensen IL. Genetic and diet-induced obesity increased intestinal tumorigenesis in the double mutant mouse model multiple intestinal neoplasia X obese via disturbed glucose regulation and inflammation. J Obes. 2015;2015:343479. doi:10.​1155/​2015/​343479.PubMedPubMedCentral
40.
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84. doi:10.​1172/​JCI29881.PubMedPubMedCentralCrossRef
41.
Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 2007;282(48):35279–92. doi:10.​1074/​jbc.​M706762200.PubMedCrossRef
42.
Strissel KJ, Stancheva Z, Miyoshi H, Perfield 2nd JW, DeFuria J, Jick Z, et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007;56(12):2910–8. doi:10.​2337/​db07-0767.PubMedCrossRef
43.
Zaldivar F, McMurray RG, Nemet D, Galassetti P, Mills PJ, Cooper DM. Body fat and circulating leukocytes in children. Int J Obes (Lond). 2006;30(6):906–11. doi:10.​1038/​sj.​ijo.​0803227.CrossRef
44.
Debnath M, Agrawal S, Agrawal A, Dubey GP. Metaflammatory responses during obesity: pathomechanism and treatment. Obes Res Clin Pract. 2015. doi:10.​1016/​j.​orcp.​2015.​10.​012.PubMed
45.
Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121(6):2111–7. doi:10.​1172/​JCI57132.PubMedPubMedCentralCrossRef
46.
Shore SA. Environmental perturbations: obesity. Compr Physiol. 2011;1(1):263–82. doi:10.​1002/​cphy.​c100017.PubMedPubMedCentral
47.
Atabek ME, Vatansev H, Erkul I. Oxidative stress in childhood obesity. J Pediatr Endocrinol Metab. 2004;17(8):1063–8.PubMed
48.
Bakker SJ RGIJ, Teerlink T, Westerhoff HV, Gans RO, Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? Atherosclerosis. 2000;148(1):17–21.PubMedCrossRef
49.
Keaney Jr JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol. 2003;23(3):434–9. doi:10.​1161/​01.​ATV.​0000058402.​34138.​11.PubMedCrossRef
50.
Lee YS, Kim AY, Choi JW, Kim M, Yasue S, Son HJ, et al. Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress. Mol Endocrinol. 2008;22(9):2176–89. doi:10.​1210/​me.​2008-0023.PubMedCrossRef
51.
Hernandez AR, Boada LD, Almeida-Gonzalez M, Mendoza Z, Ruiz-Suarez N, Valeron PF, et al. An estimation of the carcinogenic risk associated with the intake of multiple relevant carcinogens found in meat and charcuterie products. Sci Total Environ. 2015;514:33–41. doi:10.​1016/​j.​scitotenv.​2015.​01.​108.PubMedCrossRef
52.
Schut HA, Snyderwine EG. DNA adducts of heterocyclic amine food mutagens: implications for mutagenesis and carcinogenesis. Carcinogenesis. 1999;20(3):353–68.PubMedCrossRef
53.
Pei YF, Tian Q, Zhang L, Deng HW. Exploring the major sources and extent of heterogeneity in a genome-wide association meta-analysis. Ann Hum Genet. 2015. doi:10.​1111/​ahg.​12143.PubMed
54.
Holmes L, LaHurd A, Wasson E, McClarin L, Dabney K. Racial and ethnic heterogeneity in the association between total cholesterol and pediatric obesity. Int J Environ Res Public Health. 2015;13(1). doi:10.​3390/​ijerph13010019.
55.
Perl A. mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 2015;1346(1):33–44. doi:10.​1111/​nyas.​12756.PubMedPubMedCentralCrossRef
56.
Cowen S, McLaughlin SL, Hobbs G, Coad J, Martin KH, Olfert IM, et al. High-fat, high-calorie diet enhances mammary carcinogenesis and local inflammation in MMTV-PyMT mouse model of breast cancer. Cancers (Basel). 2015;7(3):1125–42. doi:10.​3390/​cancers7030828.CrossRef
57.
Crujeiras AB, Cabia B, Carreira MC, Amil M, Cueva J, Andrade S, et al. Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int J Obes (Lond). 2015. doi:10.​1038/​ijo.​2015.​208.
58.
Gorlach A, Dimova EY, Petry A, Martinez-Ruiz A, Hernansanz-Agustin P, Rolo AP, et al. Reactive oxygen species, nutrition, hypoxia and diseases: problems solved? Redox Biol. 2015;6:372–85. doi:10.​1016/​j.​redox.​2015.​08.​016.PubMedPubMedCentralCrossRef
59.
Hasan S, Suhail N, Bilal N, Ashraf GM, Zaidi SK, AlNohair S, et al. Chronic unpredictable stress deteriorates the chemopreventive efficacy of pomegranate through oxidative stress pathway. Tumour Biol. 2015. doi:10.​1007/​s13277-015-4469-9.
60.
Manna P, Jain SK. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndr Relat Disord. 2015;13(10):423–44. doi:10.​1089/​met.​2015.​0095.PubMedPubMedCentralCrossRef
61.
Hunsche C, Hernandez O, De la Fuente M. Impaired immune response in old mice suffering from obesity and premature immunosenescence in adulthood. J Gerontol A Biol Sci Med Sci. 2015. doi:10.​1093/​gerona/​glv082.PubMed
62.
Meyskens Jr FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res : Off J Am Assoc Cancer Res. 2004;10(8):2581–3.CrossRef
63.
Caslin HL, Franco RL, Crabb EB, Huang CJ, Bowen MK, Acevedo EO. The effect of obesity on inflammatory cytokine and leptin production following acute mental stress. Psychophysiology. 2015. doi:10.​1111/​psyp.​12568.PubMed
64.
Gogas H, Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, et al. Melanoma risk in association with serum leptin levels and lifestyle parameters: a case–control study. Ann Oncol. 2008;19(2):384–9. doi:10.​1093/​annonc/​mdm464.PubMedCrossRef
65.
Dayakar A, Chandrasekaran S, Veronica J, Maurya RS. Leptin induces the phagocytosis and protective immune response in Leishmania donovani infected THP-1 cell line and human PBMCs. Exp Parasitol. 2015. doi:10.​1016/​j.​exppara.​2015.​12.​002.
66.
Huang CJ, McAllister MJ, Slusher AL, Webb HE, Mock JT, Acevedo EO. Obesity-related oxidative stress: the impact of physical activity and diet manipulation. Sports Med Open. 2015;1(1):32. doi:10.​1186/​s40798-015-0031-y.PubMedPubMedCentralCrossRef
67.
Mizutani H, Fukushima S, Masuguchi S, Yamashita J, Miyashita A, Nakahara S, et al. Serum levels of leptin receptor in patients with malignant melanoma as a new tumor marker. Exp Dermatol. 2013;22(11):748–9. doi:10.​1111/​exd.​12238.PubMedCrossRef
68.
Chirumbolo S. The role of vitamin D towards immune tolerance in white adipose tissue (WAT). Endocr Metab Immune Disord Drug Targets. 2015;15(4):277–87.PubMedCrossRef
69.
Yao Y, Zhu L, He L, Duan Y, Liang W, Nie Z, et al. A meta-analysis of the relationship between vitamin D deficiency and obesity. Int J Clin Exp Med. 2015;8(9):14977–84.PubMedPubMedCentral
70.
Lagunova Z, Porojnicu AC, Grant WB, Bruland O, Moan JE. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol Nutr Food Res. 2010;54(8):1127–33. doi:10.​1002/​mnfr.​200900512.PubMed
71.
Kremer R, Campbell PP, Reinhardt T, Gilsanz V. Vitamin D status and its relationship to body fat, final height, and peak bone mass in young women. J Clin Endocrinol Metab. 2009;94(1):67–73. doi:10.​1210/​jc.​2008-1575.PubMedCrossRef
72.
Bikle DD. Vitamin D, and the skin: physiology and pathophysiology. Rev Endocr Metab Disord. 2012;13(1):3–19.PubMedPubMedCentralCrossRef
73.
Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr. 2004;79(3):362–71.PubMed
74.
Lackey DE, Olefsky JM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol. 2016;12(1):15–28. doi:10.​1038/​nrendo.​2015.​189.PubMedCrossRef
75.
Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett. 2007;112(2):61–7. doi:10.​1016/​j.​imlet.​2007.​07.​003.PubMedCrossRef
76.
De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;2013:291546. doi:10.​1155/​2013/​291546.PubMedPubMedCentralCrossRef
77.
Saraiya A, Al-Shoha A, Brodell RT. Hyperinsulinemia associated with acanthosis nigricans, finger pebbles, acrochordons, and the sign of Leser-Trelat. Endocr Pract. 2013;19(3):522–5. doi:10.​4158/​EP12192.​RA.PubMedCrossRef
78.
East HE, Subauste JS, Gandhi A, Koch CA. About secondary causes of diabetes mellitus. J Miss State Med Assoc. 2012;53(11):380–3.PubMed
79.
Cheng S, Gomez K, Serri O, Chik C, Ezzat S. The role of diabetes in acromegaly associated neoplasia. PLoS One. 2015;10(5), e0127276. doi:10.​1371/​journal.​pone.​0127276.PubMedPubMedCentralCrossRef
80.
Su Y, Carey LC, Rose JC, Pulgar VM. Leptin alters adrenal responsiveness by decreasing expression of ACTH-R, StAR, and P450c21 in hypoxemic fetal sheep. Reprod Sci. 2012;19(10):1075–84. doi:10.​1177/​1933719112442246​.PubMedPubMedCentralCrossRef
81.
Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, et al. Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep. 2010;23(4):901–7.PubMedPubMedCentralCrossRef
82.
de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer. 2004;40(16):2355–66. doi:10.​1016/​j.​ejca.​2004.​06.​003.PubMedCrossRef
83.
Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006;107(6):1331–9. doi:10.​1002/​cncr.​22126.PubMedCrossRef
84.
Mansson-Brahme E, Johansson H, Larsson O, Rutqvist LE, Ringborg U. Trends in incidence of cutaneous malignant melanoma in a Swedish population 1976–1994. Acta Oncol. 2002;41(2):138–46.PubMedCrossRef
85.
Stang A, Pukkala E, Sankila R, Soderman B, Hakulinen T. Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. Int J Cancer. 2006;119(2):380–4. doi:10.​1002/​ijc.​21836.PubMedCrossRef
86.
Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129(7):1666–74. doi:10.​1038/​jid.​2008.​423.PubMedPubMedCentralCrossRef
87.
Ortiz CA, Goodwin JS, Freeman JL. The effect of socioeconomic factors on incidence, stage at diagnosis and survival of cutaneous melanoma. Med Sci Monit. 2005;11(5):RA163–72.PubMed
88.
Pollitt RA, Clarke CA, Shema SJ, Swetter SM. California Medicaid enrollment and melanoma stage at diagnosis: a population-based study. Am J Prev Med. 2008;35(1):7–13. doi:10.​1016/​j.​amepre.​2008.​03.​026.PubMedPubMedCentralCrossRef
89.
Roetzheim RG, Pal N, Tennant C, Voti L, Ayanian JZ, Schwabe A, et al. Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst. 1999;91(16):1409–15.PubMedCrossRef
90.
Diffey B. Climate change, ozone depletion and the impact on ultraviolet exposure of human skin. Phys Med Biol. 2004;49(1):R1–11.PubMedCrossRef
91.
Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481. doi:10.​1136/​bmj.​38516.​649537.​E0.PubMedPubMedCentralCrossRef
92.
Hall HI, Jamison P, Fulton JP, Clutter G, Roffers S, Parrish P. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol. 2003;49(4):624–30.PubMedCrossRef
93.
Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch Dermatol. 1996;132(8):881–4.PubMedCrossRef
94.
Swerlick RA, Chen S. The melanoma epidemic: more apparent than real? Mayo Clin Proc. 1997;72(6):559–64. doi:10.​1016/​S0025-6196(11)63306-5.PubMedCrossRef
95.
Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res (Phila). 2010;3(2):233–45. doi:10.​1158/​1940-6207.​CAPR-09-0108.CrossRef
96.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040–59. doi:10.​1016/​j.​ejca.​2005.​03.​034.PubMedCrossRef
97.
Wheless L, Black J, Alberg AJ. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010;19(7):1686–95. doi:10.​1158/​1055-9965.​EPI-10-0243.PubMedCrossRef
98.
Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. Curr Dermatol Rep. 2013;2(1):24–34. doi:10.​1007/​s13671-012-0035-5.PubMedPubMedCentralCrossRef
99.
Pappo AS, Armstrong GT, Liu W, Srivastava DK, McDonald A, Leisenring WM, et al. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2013;60(3):461–6. doi:10.​1002/​pbc.​24266.PubMedCrossRef
100.
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60. doi:10.​1016/​j.​ejca.​2004.​10.​016.PubMedCrossRef
101.
Rigel DS, Rigel EG, Rigel AC. Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol. 1999;40(1):114–6.PubMedCrossRef
102.
Bulliard JL. Site-specific risk of cutaneous malignant melanoma and pattern of sun exposure in New Zealand. Int J Cancer. 2000;85(5):627–32.PubMedCrossRef
103.
Parisi AV, Kimlin MG, Lester R, Turnbull D. Lower body anatomical distribution of solar ultraviolet radiation on the human form in standing and sitting postures. J Photochem Photobiol B. 2003;69(1):1–6.PubMedCrossRef
104.
Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County. Minnesota Mayo Clin Proc. 2012;87(4):328–34. doi:10.​1016/​j.​mayocp.​2012.​01.​010.PubMedCrossRef
105.
Stryker WS, Stampfer MJ, Stein EA, Kaplan L, Louis TA, Sober A, et al. Diet, plasma levels of beta-carotene and alpha-tocopherol, and risk of malignant melanoma. Am J Epidemiol. 1990;131(4):597–611.PubMed
106.
Bain C, Green A, Siskind V, Alexander J, Harvey P. Diet and melanoma. An exploratory case–control study. Ann Epidemiol. 1993;3(3):235–8.PubMedCrossRef
107.
Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D, et al. Diet and melanoma in a case–control study. Cancer Epidemiol Biomarkers Prev. 2004;13(6):1042–51.PubMed
108.
Meyskens Jr FL, Farmer PJ, Anton-Culver H. Diet and melanoma in a case–control study. Cancer Epidemiol Biomarkers Prev. 2005;14(1):293.PubMed
109.
Le Marchand L, Saltzman BS, Hankin JH, Wilkens LR, Franke AA, Morris SJ, et al. Sun exposure, diet, and melanoma in Hawaii Caucasians. Am J Epidemiol. 2006;164(3):232–45. doi:10.​1093/​aje/​kwj115.PubMedCrossRef
110.
Nicolopoulou-Stamati P, Hens L, Sasco AJ. Cosmetics as endocrine disruptors: are they a health risk? Rev Endocr Metab Disord. 2015;16(4):373–83.PubMedCrossRef
111.
Holland KT, Bojar RA. Cosmetics: what is their influence on the skin microflora? Am J Clin Dermatol. 2002;3(7):445–9.PubMedCrossRef
112.
Karpuzoglu E, Holladay SD, Gogal Jr RM. Parabens: potential impact of low-affinity estrogen receptor binding chemicals on human health. J Toxicol Environ Health B Crit Rev. 2013;16(5):321–35. doi:10.​1080/​10937404.​2013.​809252.PubMedCrossRef
113.
Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–17. doi:10.​1016/​j.​ejca.​2011.​04.​023.PubMedCrossRef
114.
Ward EM, Burnett CA, Ruder A, Davis-King K. Industries and cancer. Cancer Causes Control. 1997;8(3):356–70.PubMedCrossRef
115.
Sinks T, Steele G, Smith AB, Watkins K, Shults RA. Mortality among workers exposed to polychlorinated biphenyls. Am J Epidemiol. 1992;136(4):389–98.PubMed
116.
Loomis D, Browning SR, Schenck AP, Gregory E, Savitz DA. Cancer mortality among electric utility workers exposed to polychlorinated biphenyls. Occup Environ Med. 1997;54(10):720–8.PubMedPubMedCentralCrossRef
117.
Robinson CF, Petersen M, Palu S. Mortality patterns among electrical workers employed in the U.S. construction industry, 1982–1987. Am J Ind Med. 1999;36(6):630–7.PubMedCrossRef
118.
Nelemans PJ, Scholte R, Groenendal H, Kiemeney LA, Rampen FH, Ruiter DJ, et al. Melanoma and occupation: results of a case–control study in The Netherlands. Br J Ind Med. 1993;50(7):642–6.PubMedPubMedCentral
119.
Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab. 2003;284(3):E468–74. doi:10.​1152/​ajpendo.​00434.​2002.PubMedCrossRef
120.
Danforth CH. Hereditary adiposity in mice. Obes Res. 1996;4(1):96–100.PubMedCrossRef
121.
Dickies MM. A new viable yellow mutation in the house mouse. J Hered. 1962;53:84–6.PubMed
122.
Heston WE, Vlahakis G. Influence of the Ay gene on mammary-gland tumors, hepatomas, and normal growth in mice. J Natl Cancer Inst. 1961;26:969–83.PubMed
123.
Heston WE, Vlahakis G. C3H-Avy—a high hepatoma and high mammary tumor strain of mice. J Natl Cancer Inst. 1968;40(6):1161–6.PubMed
124.
Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL. Obesity, diabetes, and neoplasia in yellow A(vy)/- mice: ectopic expression of the agouti gene. FASEB J. 1994;8(8):479–88.PubMed
125.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–7. doi:10.​1038/​509.PubMedCrossRef
126.
Millington GW. Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin Exp Dermatol. 2006;31(3):407–12. doi:10.​1111/​j.​1365-2230.​2006.​02128.​x.PubMedCrossRef
127.
Ramachandrappa S, Farooqi IS. Genetic approaches to understanding human obesity. J Clin Invest. 2011;121(6):2080–6. doi:10.​1172/​JCI46044.PubMedPubMedCentralCrossRef
128.
D’Orazio JA, Nobuhisa T, Cui R, Arya M, Spry M, Wakamatsu K, et al. Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning. Nature. 2006;443(7109):340–4. doi:10.​1038/​nature05098.PubMedCrossRef
129.
Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007;128(5):853–64. doi:10.​1016/​j.​cell.​2006.​12.​045.PubMedCrossRef
130.
Sato HNY, Chrousos GP, Ichihashi M, Funasak Y. The expression of corticotropin-releasing hormone in melanoma. Pigment Cell Res. 2002;15(2):98–103.PubMedCrossRef
131.
Millington GW. The role of proopiomelanocortin (POMC) neurones in feeding behaviour. Nutr Metab (Lond). 2007;4:18. doi:10.​1186/​1743-7075-4-18.CrossRef
132.
Sharma SD, Katiyar SK. Leptin deficiency-induced obesity exacerbates ultraviolet B radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet B-irradiated mouse skin. Toxicol Appl Pharmacol. 2010;244(3):328–35. doi:10.​1016/​j.​taap.​2010.​01.​010.PubMedCrossRef
133.
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681–96. doi:10.​1016/​j.​cell.​2015.​05.​044.CrossRef
134.
Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207(1):12–22. doi:10.​1002/​jcp.​20472.PubMedCrossRef
135.
Tessitore L, Vizio B, Jenkins O, De Stefano I, Ritossa C, Argiles JM, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med. 2000;5(4):421–6.PubMed
136.
Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, et al. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab. 2002;46(3–4):147–51.PubMedCrossRef
137.
Stattin P, Palmqvist R, Soderberg S, Biessy C, Ardnor B, Hallmans G, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep. 2003;10(6):2015–21.PubMed
138.
Arnardottir ES, Maislin G, Jackson N, Schwab RJ, Benediktsdottir B, Teff K, et al. The role of obesity, different fat compartments and sleep apnea severity in circulating leptin levels: the Icelandic Sleep Apnea Cohort study. Int J Obes (Lond). 2013;37(6):835–42. doi:10.​1038/​ijo.​2012.​138.CrossRef
139.
Leroy P, Dessolin S, Villageois P, Moon BC, Friedman JM, Ailhaud G, et al. Expression of ob gene in adipose cells. Regulation by insulin. J Biol Chem. 1996;271(5):2365–8.PubMedCrossRef
140.
Zhang HH, Kumar S, Barnett AH, Eggo MC. Tumour necrosis factor-alpha exerts dual effects on human adipose leptin synthesis and release. Mol Cell Endocrinol. 2000;159(1–2):79–88.PubMedCrossRef
141.
Dagogo-Jack S, Selke G, Melson AK, Newcomer JW. Robust leptin secretory responses to dexamethasone in obese subjects. J Clin Endocrinol Metab. 1997;82(10):3230–3. doi:10.​1210/​jcem.​82.​10.​4154.PubMed
142.
Machinal-Quelin F, Dieudonne MN, Pecquery R, Leneveu MC, Giudicelli Y. Direct in vitro effects of androgens and estrogens on ob gene expression and leptin secretion in human adipose tissue. Endocrine. 2002;18(2):179–84. doi:10.​1385/​ENDO:​18:​2:​179.PubMedCrossRef
143.
Fain JN, Leffler CW, Bahouth SW. Eicosanoids as endogenous regulators of leptin release and lipolysis by mouse adipose tissue in primary culture. J Lipid Res. 2000;41(10):1689–94.PubMed
144.
Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, et al. Elevated serum leptin levels are associated with an increased risk of sentinel lymph node metastasis in cutaneous melanoma. Medicine (Baltimore). 2016;95(11), e3073. doi:10.​1097/​MD.​0000000000003073​.CrossRef
145.
Jung JI, Cho HJ, Jung YJ, Kwon SH, Her S, Choi SS, et al. High-fat diet-induced obesity increases lymphangiogenesis and lymph node metastasis in the B16F10 melanoma allograft model: roles of adipocytes and M2-macrophages. Int J Cancer. 2015;136(2):258–70. doi:10.​1002/​ijc.​28983.PubMedCrossRef
146.
McMurphy T, Xiao R, Magee D, Slater A, Zabeau L, Tavernier J, et al. The anti-tumor activity of a neutralizing nanobody targeting leptin receptor in a mouse model of melanoma. PLoS ONE. 2014;9(2), e89895. doi:10.​1371/​journal.​pone.​0089895.PubMedPubMedCentralCrossRef
147.
Emilsson V, Liu YL, Cawthorne MA, Morton NM, Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes. 1997;46(2):313–6.PubMedCrossRef
148.
Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, et al. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets, and in vivo, in mice. J Clin Invest. 1997;100(11):2729–36. doi:10.​1172/​JCI119818.PubMedPubMedCentralCrossRef
149.
Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab. 2009;297(6):E1247–59. doi:10.​1152/​ajpendo.​00274.​2009.PubMedPubMedCentralCrossRef
150.
Wang MY, Lee Y, Unger RH. Novel form of lipolysis induced by leptin. J Biol Chem. 1999;274(25):17541–4.PubMedCrossRef
151.
Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269(5223):546–9.PubMedCrossRef
152.
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543–6.PubMedCrossRef
153.
Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995;269(5223):540–3.PubMedCrossRef
154.
Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature. 1995;377(6549):530–2. doi:10.​1038/​377530a0.PubMedCrossRef
155.
Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996;348(9021):159–61.PubMedCrossRef
156.
El-Haschimi K, Pierroz DD, Hileman SM, Bjorbaek C, Flier JS. Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J Clin Invest. 2000;105(12):1827–32. doi:10.​1172/​JCI9842.PubMedPubMedCentralCrossRef
157.
Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte Jr D. Cerebrospinal fluid leptin levels: relationship to plasma levels and to adiposity in humans. Nat Med. 1996;2(5):589–93.PubMedCrossRef
158.
Belouzard S, Delcroix D, Rouille Y. Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway. J Biol Chem. 2004;279(27):28499–508. doi:10.​1074/​jbc.​M400508200.PubMedCrossRef
159.
Diano S, Kalra SP, Horvath TL. Leptin receptor immunoreactivity is associated with the Golgi apparatus of hypothalamic neurons and glial cells. J Neuroendocrinol. 1998;10(9):647–50.PubMedCrossRef
160.
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature. 1997;387(6636):903–8. doi:10.​1038/​43185.PubMedCrossRef
161.
Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 1998;18(3):213–5. doi:10.​1038/​ng0398-213.PubMedCrossRef
162.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32. doi:10.​1038/​372425a0.PubMedCrossRef
163.
Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52(15):1201–10. doi:10.​1016/​j.​jacc.​2008.​05.​060.PubMedPubMedCentralCrossRef
164.
Mantzoros CS, Liolios AD, Tritos NA, Kaklamani VG, Doulgerakis DE, Griveas I, et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res. 1998;6(3):179–86.PubMedCrossRef
165.
Traish AM, Zitzmann M. The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Rev Endocr Metab Disord. 2015;16(3):249–68. doi:10.​1007/​s11154-015-9323-2.PubMedCrossRef
166.
Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res. 2011;43(03):153–64.PubMedCrossRef
167.
Coppari R, Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov. 2012;11(9):692–708. doi:10.​1038/​nrd3757.PubMedPubMedCentralCrossRef
168.
Stanley BG, Leibowitz SF. Neuropeptide Y injected in the paraventricular hypothalamus: a powerful stimulant of feeding behavior. Proc Natl Acad Sci U S A. 1985;82(11):3940–3.PubMedPubMedCentralCrossRef
169.
Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009;9(1):35–51. doi:10.​1016/​j.​cmet.​2008.​12.​004.PubMedCrossRef
170.
Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008;135(1):61–73. doi:10.​1016/​j.​cell.​2008.​07.​043.PubMedPubMedCentralCrossRef
171.
Ogimoto K, Harris Jr MK, Wisse BE. MyD88 is a key mediator of anorexia, but not weight loss, induced by lipopolysaccharide and interleukin-1 beta. Endocrinology. 2006;147(9):4445–53. doi:10.​1210/​en.​2006-0465.PubMedCrossRef
172.
Ozcan U, Ozcan L, Yilmaz E, Duvel K, Sahin M, Manning BD, et al. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell. 2008;29(5):541–51. doi:10.​1016/​j.​molcel.​2007.​12.​023.PubMedPubMedCentralCrossRef
173.
Hosoi T, Sasaki M, Miyahara T, Hashimoto C, Matsuo S, Yoshii M, et al. Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol. 2008;74(6):1610–9. doi:10.​1124/​mol.​108.​050070.PubMedCrossRef
174.
Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007;4(1):1–13.PubMed
175.
Chen K, Li F, Li J, Cai H, Strom S, Bisello A, et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat Med. 2006;12(4):425–32. doi:10.​1038/​nm1372.PubMedCrossRef
176.
Amjadi F, Javanmard SH, Zarkesh-Esfahani H, Khazaei M, Narimani M. Leptin promotes melanoma tumor growth in mice related to increasing circulating endothelial progenitor cells numbers and plasma NO production. J Exp Clin Cancer Res. 2011;30:21. doi:10.​1186/​1756-9966-30-21.PubMedPubMedCentralCrossRef
177.
Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol. 2007;170(1):1–15. doi:10.​2353/​ajpath.​2007.​060302.PubMedPubMedCentralCrossRef
178.
Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281(36):26320–8. doi:10.​1074/​jbc.​M601991200.PubMedCrossRef
179.
Ribatti D, Nico B, Belloni AS, Vacca A, Roncali L, Nussdorfer GG. Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2. Int J Mol Med. 2001;8(3):265–8.PubMed
180.
Lago R, Gomez R, Lago F, Gomez-Reino J, Gualillo O. Leptin beyond body weight regulation—current concepts concerning its role in immune function and inflammation. Cell Immunol. 2008;252(1–2):139–45. doi:10.​1016/​j.​cellimm.​2007.​09.​004.PubMedCrossRef
181.
Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord. 2002;26(4):577–80.PubMedCrossRef
182.
Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413–37. doi:10.​1146/​annurev.​physiol.​62.​1.​413.PubMedCrossRef
183.
Grosfeld A, Andre J, Hauguel-De Mouzon S, Berra E, Pouyssegur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem. 2002;277(45):42953–7. doi:10.​1074/​jbc.​M206775200.PubMedCrossRef
184.
Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A. 2004;101(8):2476–81.PubMedPubMedCentralCrossRef
185.
Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood. 2000;96(5):1723–32.PubMed
186.
Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res. 2005;28(11):1263–9.PubMedCrossRef
187.
Ogunwobi OO, Beales IL. Adiponectin stimulates proliferation and cytokine secretion in colonic epithelial cells. Regul Pept. 2006;134(2–3):105–13. doi:10.​1016/​j.​regpep.​2006.​02.​001.PubMedCrossRef
188.
Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006;340(4):1158–66. doi:10.​1016/​j.​bbrc.​2005.​12.​103.PubMedCrossRef
189.
Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res. 2007;39(1):9–13. doi:10.​1055/​s-2007-956518.PubMedCrossRef
190.
Mantzoros CS, Trakatelli M, Gogas H, Dessypris N, Stratigos A, Chrousos GP, et al. Circulating adiponectin levels in relation to melanoma: a case–control study. Eur J Cancer. 2007;43(9):1430–6. doi:10.​1016/​j.​ejca.​2007.​03.​026.PubMedCrossRef
191.
Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D. The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract. 2010;16(5):864–73. doi:10.​4158/​EP10098.​RA.PubMedCrossRef
192.
Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, Leroith D, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res. 2008;68(10):2680–8.CrossRef
193.
Sadagurski MYS, Weingarten G, Holzenberger M, Rhodes CJ, Breitkreutz D, Leroith D, et al. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol. 2006;26(7):2675–87.PubMedPubMedCentralCrossRef
194.
Chi M, Ye Y, Zhang XD, Chen J. Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. Drug Des Devel Ther. 2014;8:255–62. doi:10.​2147/​DDDT.​S53568.PubMedPubMedCentral
195.
Kucera R, Treskova I, Vrzalova J, Svobodova S, Topolcan O, Fuchsova R, et al. Evaluation of IGF1 serum levels in malignant melanoma and healthy subjects. Anticancer Res. 2014;34(9):5217–20.PubMed
196.
Naspi A, Panasiti V, Abbate F, Roberti V, Devirgiliis V, Curzio M, et al. Insulin-like-growth-factor-binding-protein-3 (IGFBP-3) contrasts melanoma progression in vitro and in vivo. PLoS One. 2014;9(6), e98641. doi:10.​1371/​journal.​pone.​0098641.PubMedPubMedCentralCrossRef
197.
Jones SA, Morand EF. Glucocorticoids in 2015: new answers to old problems. Nat Rev Rheumatol. 2015. doi:10.​1038/​nrrheum.​2015.​176.
198.
Bhakoo HS, Milholland RJ, Lopez R, Karakousis C, Rosen F. High incidence and characterization of glucocorticoid receptors in human malignant melanoma. J Natl Cancer Inst. 1981;66(1):21–5.PubMed
199.
Dobos J, Kenessey I, Timar J, Ladanyi A. Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells. Pathol Oncol Res. 2011;17(3):729–34. doi:10.​1007/​s12253-011-9377-8.PubMedCrossRef
200.
Spencer SJ, Tilbrook A. The glucocorticoid contribution to obesity. Stress. 2011;14(3):233–46. doi:10.​3109/​10253890.​2010.​534831.PubMedCrossRef
201.
Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, et al. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology. 2000;141(2):560–3. doi:10.​1210/​endo.​141.​2.​7297.PubMed
202.
Shoag J, Haq R, Zhang M, Liu L, Rowe GC, Jiang A, et al. PGC-1 coactivators regulate MITF and the tanning response. Mol Cell. 2013;49(1):145–57. doi:10.​1016/​j.​molcel.​2012.​10.​027.PubMedCrossRef
203.
Price RA, Li WD, Zhao H. FTO gene SNPs associated with extreme obesity in cases, controls and extremely discordant sister pairs. BMC Med Genet. 2008;9:4. doi:10.​1186/​1471-2350-9-4.PubMedPubMedCentralCrossRef
204.
Ghosh S, Murinova L, Trnovec T, Loffredo CA, Washington K, Mitra PS, et al. Biomarkers linking PCB exposure and obesity. Curr Pharm Biotechnol. 2014;15(11):1058–68.PubMedPubMedCentralCrossRef
205.
De Coster S, van Larebeke N. Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health. 2012;2012:713696. doi:10.​1155/​2012/​713696.PubMedPubMedCentralCrossRef
206.
Koch CA. EDITORIAL: “The Koch’s” view on the sense of taste in endocrinology. Rev Endocr Metab Disord. 2016;17(2):143–7. doi:10.​1007/​s11154-016-9383-y.PubMedCrossRef
207.
Brill MJ, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CA. Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet. 2012;51(5):277–304. doi:10.​2165/​11599410-000000000-00000.PubMedCrossRef
208.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20. doi:10.​1001/​jama.​2013.​284427.PubMedCrossRef
209.
McDonald E, Freedman DM, Alexander BH, Doody MM, Tucker MA, Linet MS, et al. Prescription diuretic use and risk of basal cell carcinoma in the nationwide U.S. radiologic technologists cohort. Cancer Epidemiol Biomarkers Prev. 2014;23(8):1539–45. doi:10.​1158/​1055-9965.​EPI-14-0251.PubMedPubMedCentralCrossRef
210.
Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case–control study. J Invest Dermatol. 2013;133(8):1950–5. doi:10.​1038/​jid.​2013.​33.PubMedPubMedCentralCrossRef
211.
Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(11):2942–9. doi:10.​1158/​1055-9965.​EPI-10-0652.PubMedCrossRef
212.
Ruiter R, Visser LE, Eijgelsheim M, Rodenburg EM, Hofman A, Coebergh JW, et al. High-ceiling diuretics are associated with an increased risk of basal cell carcinoma in a population-based follow-up study. Eur J Cancer. 2010;46(13):2467–72. doi:10.​1016/​j.​ejca.​2010.​04.​024.PubMedCrossRef
213.
Glatz M, Hofbauer GF. Phototoxic and photoallergic cutaneous drug reactions. Chem Immunol Allergy. 2012;97:167–79. doi:10.​1159/​000335630.PubMedCrossRef
214.
Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf. 2002;25(5):345–72.PubMedCrossRef
215.
Stern RS. Photocarcinogenicity of drugs. Toxicol Lett. 1998;102–103:389–92.
216.
Stern RS, Bigby M. An expanded profile of cutaneous reactions to nonsteroidal anti-inflammatory drugs. Reports to a specialty-based system for spontaneous reporting of adverse reactions to drugs. JAMA. 1984;252(11):1433–7.PubMedCrossRef
217.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Risk of skin reactions when using ibuprofen-based medicines. Expert Opin Drug Saf. 2005;4(5):837–48. doi:10.​1517/​14740338.​4.​5.​837.PubMedCrossRef
218.
Finch LE, Tomiyama AJ. Comfort eating, psychological stress, and depressive symptoms in young adult women. Appetite. 2015;95:239–44. doi:10.​1016/​j.​appet.​2015.​07.​017.PubMedCrossRef
219.
Bliss SA, Warnock JK. Psychiatric medications: adverse cutaneous drug reactions. Clin Dermatol. 2013;31(1):101–9. doi:10.​1016/​j.​clindermatol.​2011.​11.​014.PubMedCrossRef
220.
Borras L, Huguelet P. A case report of photosensitivity to amisulpride. Prim Care Companion J Clin Psychiatry. 2007;9(2):153.PubMedPubMedCentralCrossRef
221.
Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol. 2002;3(9):629–36.PubMedCrossRef
222.
Mennella JA, Bobowski NK, Reed DR. The development of sweet taste: from biology to hedonics. Rev Endocr Metab Disord. 2016;17(2):171–8. doi:10.​1007/​s11154-016-9360-5.PubMedCrossRef
223.
Iwasaki JK, Srivastava D, Moy RL, Lin HJ, Kouba DJ. The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol. 2012;66(5):e167–78. doi:10.​1016/​j.​jaad.​2010.​06.​054.PubMedCrossRef
224.
Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016;48(4):398–406. doi:10.​1038/​ng.​3525.PubMedCrossRef
225.
Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283–7. doi:10.​1001/​archdermatol.​2010.​19.PubMedCrossRef
226.
Makrantonaki EZC. Molecular mechanisms of skin aging: state of the art. Acad Sci. 2007;1119:40–50.CrossRef
227.
Yan W, Wistuba II, Emmert-Buck MR, Erickson HS. Squamous cell carcinoma—similarities and differences among anatomical sites. Am J Cancer Res. 2011;1(3):275–300.PubMedCrossRef
228.
Ibiebele TI, van der Pols JC, Hughes MC, Marks GC, Williams GM, Green AC. Dietary pattern in association with squamous cell carcinoma of the skin: a prospective study. Am J Clin Nutr. 2007;85(5):1401–8.PubMed
229.
Inoue T, Toda S, Narisawa Y, Sugihara H. Subcutaneous adipocytes promote the differentiation of squamous cell carcinoma cell line (DJM-1) in collagen gel matrix culture. J Invest Dermatol. 2001;117(2):244–50. doi:10.​1046/​j.​0022-202x.​2001.​01431.​x.PubMedCrossRef
230.
Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262–9. doi:10.​1056/​NEJMra044151.PubMedCrossRef
231.
Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–79.PubMedPubMedCentral
232.
Espinosa P, Pfeiffer RM, Garcia-Casado Z, Requena C, Landi MT, Kumar R, et al. Risk factors for keratinocyte skin cancer in patients diagnosed with melanoma, a large retrospective study. Eur J Cancer. 2015;53:115–24. doi:10.​1016/​j.​ejca.​2015.​10.​058.PubMedCrossRef
233.
Reinau D, Surber C, Jick SS, Meier CR. Epidemiology of basal cell carcinoma in the United Kingdom: incidence, lifestyle factors, and comorbidities. Br J Cancer. 2014;111(1):203–6. doi:10.​1038/​bjc.​2014.​265.PubMedPubMedCentralCrossRef
234.
Baxter JM, Patel AN, Varma S. Facial basal cell carcinoma. BMJ. 2012;345, e5342. doi:10.​1136/​bmj.​e5342.PubMedCrossRef
235.
Cheng P, Weng SD, Chiang CH, Lai FJ. Relationship between arsenic-containing drinking water and skin cancers in the arseniasis endemic areas in Taiwan. J Dermatol. 2016;43(2):181–6.PubMedCrossRef
236.
Poschl G, Seitz HK. Alcohol and cancer. Alcohol Alcohol. 2004;39(3):155–65.PubMedCrossRef
237.
Saladi RN, Nektalova T, Fox JL. Induction of skin carcinogenicity by alcohol and ultraviolet light. Clin Exp Dermatol. 2010;35(1):7–11. doi:10.​1111/​j.​1365-2230.​2009.​03465.​x.PubMedCrossRef
238.
Song F, Qureshi AA, Gao X, Li T, Han J. Smoking and risk of skin cancer: a prospective analysis and a meta-analysis. Int J Epidemiol. 2012;41(6):1694–705. doi:10.​1093/​ije/​dys146.PubMedPubMedCentralCrossRef
239.
Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol. 2012;148(8):939–46. doi:10.​1001/​archdermatol.​2012.​1374.PubMedCrossRef
240.
Hughes MC, Olsen CM, Williams GM, Green AC. A prospective study of cigarette smoking and basal cell carcinoma. Arch Dermatol Res. 2014;306(9):851–6. doi:10.​1007/​s00403-014-1503-5.PubMedCrossRef
241.
Henderson MT, Kubo JT, Desai M, David SP, Tindle H, Sinha AA, et al. Smoking behavior and association of melanoma and nonmelanoma skin cancer in the Women’s Health Initiative. J Am Acad Dermatol. 2015;72(1):190–1. doi:10.​1016/​j.​jaad.​2014.​09.​024. e3.PubMedPubMedCentralCrossRef
242.
Trost SG, Owen N, Bauman AE, Sallis JF, Brown W. Correlates of adults’ participation in physical activity: review and update. Med Sci Sports Exerc. 2002;34(12):1996–2001. doi:10.​1249/​01.​MSS.​0000038974.​76900.​92.PubMedCrossRef